MDA-MB-231 D3H2LN-Luc TetOn-3G cell line
Invented by Heather Mckinnon , Justin Bower , Daniel Croft
- References (2)
- Inventor Info
|Parental Line||MDA-MB-231 D3H2LN-Luc|
|Disease Keywords||Triple negative breast cancer (TNBC)|
This cell line contains a tetracyline inducible promoter construct ready for cloning in a gene of interest. The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Unbekandt et al., 2014 introduced their genes of interest, the kinases MRCKβ, ROCK1 and ROCK2 under the tetracycline inducible promoter, to study the impact of their expression and inhibition on migration of the cells.
Useful for the study of breast cancer cell cytoskeleton reorganisation, cell migration and the development of therapies that inhibit the ability of primary tumours to metastasize. This cell line is derived from a triple negative breast cancer (TNBC) meaning it does not express oestrogen, progesterone or HER2 receptors.
|Production Details||Generated an MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G|
|Conditional Description||When a gene of interest is introduced under the control of the tetracycline (Tet)-regulated transactivator Tet-On 3G expression can be induced by administration of doxycycline. Luciferase expression is non-conditional.|
|Research Area||Cancer, Cell Structure and Motility, Drug Discovery & Development, Genetic Studies Tools|
|Growth/Phenotype Keywords||Adherent cell line|
|Recommended Growing Conditions||10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine|
|Positive Control||HeLa TetOn-3G|
|Notes||Tet-On System owned by TET Systems GmbH & Co. KG.|
There are 2 reference entries for this reagent.View All References